Company / Cash & Equivalents
Matinas BioPharma Holdings, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$7.3M
FY2024
5-year range
$6.8M / $21.0M
FY2020-FY2024
Trend
+6.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $3M in FY2015 to $22M in FY2019.
Based on SEC 10-K filings.
$7M in FY2024 with a 5-year CAGR of -20.0%.
Declined from $21M to $7M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -29.8%
- 5-Year CAGR
- -20.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -20.0%, indicating a declining trend.
- In FY2024, cash & equivalents increased 6.6% year-over-year.
- Peak cash & equivalents was recorded in FY2019.
- Lowest cash & equivalents in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $7.3M | +6.6% |
| FY2023 | $6.8M | -67.5% |
| FY2022 | $21.0M | +0.0% |
| FY2021 | $21.0M | +69.2% |
| FY2020 | $12.4M | -43.9% |
| FY2019 | $22.2M | +203.4% |
| FY2018 | $7.3M | +78.0% |
| FY2017 | $4.1M | +0.0% |
| FY2016 | $4.1M | +27.2% |
| FY2015 | $3.2M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026